caa a22 4500 469116900 CHVBK 20180323133127.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF00170946 doi (NATIONALLICENCE)springer-10.1007/BF00170946 Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma [Elektronische Daten] Final report of a prospective phase I-II dose response study [D. Fulton, R. Urtasun, I. Scott-Brown, E. Johnson, B. Mielke, B. Curry, D. Huyser-Wierenga, J. Hanson, M. Feldstein] We attempted to show a dose effect relationship for radiation therapy by treating patients harbouring malignant glioma with increasing doses of radiation in a step-wise fashion. We postulated that no increase in delayed toxicity would be seen because we used hyperfractionation technique. Between January 1981 and December 1988 we treated 280 patients three times daily at 4 hour intervals. 100 patients received a total dose of 6141 cGy, 73 patients received 7120 cGy, and 107 patients received 8000 cGy. CCNU was given at the time of tumor progression following radiotherapy. Median time to tumor progression was 28 weeks for patients who received 6141 cGy, 27 weeks for patients who received 7120 cGy and 36 weeks for patients who received 8000 cGy. Median survival was 46 weeks for patients who received 6141 cGy, 38 weeks for patients who received 7120 cGy and 45 weeks for patients who received 8000 cGy. There was no statistically significant difference in either time to tumor progression or survival among the three treatment arms and no dose response effect was seen. There was no increase in delayed radiation toxicity when the total radiation dose was increased up to 8000 cGy. Kluwer Academic Publishers, 1992 hyperfractionation nationallicence malignant glioma nationallicence radiation therapy nationallicence Fulton D. Department of Radiation Oncology, Cross Cancer Institute and University of Alberta, Canada aut Urtasun R. Department of Radiation Oncology, Cross Cancer Institute and University of Alberta, Canada aut Scott-Brown I. Department of Radiation Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Canada aut Johnson E. Department of Pathology, University of Alberta, Edmonton, Canada aut Mielke B. Department of Pathology, University of Alberta, Edmonton, Canada aut Curry B. Department of Pathology, University of Calgary, Calgary, Canada aut Huyser-Wierenga D. Department of Radiation Oncology, Cross Cancer Institute and University of Alberta, Canada aut Hanson J. Department of Epidemiology, Cross Cancer Institute, University of Alberta, Edmonton, Canada aut Feldstein M. Frontier Science and Technology, Research Foundation Inc., Brookline, Massachusetts aut Journal of Neuro-Oncology Kluwer Academic Publishers 14/1(1992-09-01), 63-72 0167-594X 14:1<63 1992 14 11060 https://doi.org/10.1007/BF00170946 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00170946 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fulton D. Department of Radiation Oncology, Cross Cancer Institute and University of Alberta, Canada aut NATIONALLICENCE 700 1- Urtasun R. Department of Radiation Oncology, Cross Cancer Institute and University of Alberta, Canada aut NATIONALLICENCE 700 1- Scott-Brown I. Department of Radiation Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Canada aut NATIONALLICENCE 700 1- Johnson E. Department of Pathology, University of Alberta, Edmonton, Canada aut NATIONALLICENCE 700 1- Mielke B. Department of Pathology, University of Alberta, Edmonton, Canada aut NATIONALLICENCE 700 1- Curry B. Department of Pathology, University of Calgary, Calgary, Canada aut NATIONALLICENCE 700 1- Huyser-Wierenga D. Department of Radiation Oncology, Cross Cancer Institute and University of Alberta, Canada aut NATIONALLICENCE 700 1- Hanson J. Department of Epidemiology, Cross Cancer Institute, University of Alberta, Edmonton, Canada aut NATIONALLICENCE 700 1- Feldstein M. Frontier Science and Technology, Research Foundation Inc., Brookline, Massachusetts aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 14/1(1992-09-01), 63-72 0167-594X 14:1<63 1992 14 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer